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Abstract 
Background: Acute respiratory distress syndrome (ARDS) remains a common organ dysfunction in the critically ill 
patient. Mechanisms for its development have focused on immune mediated causes, aspects of our understanding 
are not complete, and we lack biomarkers.
Design, setting, and subjects: Blood and bronchial alveolar lavage fluid (BAL) from humans (n = 10–13) with ARDS 
and controls (n = 5–10) as well as a murine model of ARDS (n = 5–6) with controls (n = 6–7) were studied.
Methods: ARDS was induced in mice by hemorrhagic shock (day 1) followed by poly‑microbial sepsis (day 2). Sam‑
ples were then collected on the third day after the animals were euthanized. Ex vivo experiments used splenocytes 
from animals with ARDS cultured with and without soluble programmed death receptor‑1 (sPD‑1).
Results: Levels of sPD‑1 are increased in both the serum (11,429.3 pg/mL(SD 2133.3) vs. 8061.4(SD 4187.8), p = 0.036) 
and bronchial alveolar lavage (BAL) fluid (6,311.1 pg/mL(SD 3758.0) vs. 90.7 pg/mL(SD 202.8), p = 0.002) of humans 
with ARDS. Similar results are seen in the serum (9396.1 pg/mL(SD 1546.0) vs. 3464.5 pg/mL(SD 2511.8), p = 0.001) 
and BAL fluid (2891.7 pg/mL(SD 868.1) vs. 1385.9 pg/mL(SD 927.8), p = 0.012) of mice. sPD‑1 levels in murine blood 
(AUC = 1(1–1), p = 0.006), murine BAL fluid (AUC = 0.905(0.717–1.093), p = 0.015), and human BAL (AUC = 1(1–1), 
p = 0.001) fluid predicted ARDS. To assess the importance of sPD‑1 in ARDS, ex vivo experiments were undertaken. 
BAL fluid from mice with ARDS dampens the TNF‑α production compared to cells cultured with BAL lacking sPD‑1 
(2.7 pg/mL(SD 3.8) vs. 52.38 pg/mL(SD 25.1), p = 0.002).
Conclusions: This suggests sPD‑1 is elevated in critical illness and may represent a potential biomarker for ARDS. 
In addition, sPD‑1 has an anti‑inflammatory mechanism in conditions of marked stress and aids in the resolution of 
severe inflammation. sPD‑1 could be used to not only diagnose ARDS, but may be a potential therapy.
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Background
Acute respiratory distress syndrome (ARDS) is seen in 
critically ill patients [1] affecting 190,000 patients each 
year in the United States [2]. The mechanisms of ARDS 
are not fully understood but the immune system is impli-
cated. Neutrophils and the epithelial/endothelial cell bor-
der dysfunction in the lung are potential contributors to 
ARDS pathophysiology [2, 3].
Programmed death receptor-1 (PD-1) is an immune 
modulating/co-inhibitory cell-surface protein involved in 
chronic conditions such as cancer, autoimmune diseases, 
and viral infection [4, 5]. Recently, acute conditions like 
sepsis and ARDS have been influenced by the expression 
of PD-1. In both humans and mice, PD-1 appears to play 
a role in the pathology as well as outcomes from sep-
sis [6–8] and ARDS [9]. In sepsis the influence of PD-1 
appears to be modulated through expression on mac-
rophages as survival is improved in animals lacking PD-1 
[8]. In addition animals in which PD-1 antibody is admin-
istered have enhanced survival and clinical trials for PD-1 
in sepsis are planned [6]. The survival benefit of mice 
lacking PD-1 with ARDS appears to be due to alterations 
in cell ratio, TNF expression and neutrophil function [9].
PD-1 mediates its inhibitory action(s) via cell-surface 
ligands. There are reports of a soluble form of PD-1 (sPD-
1) due to alternative splicing [10] with levels present in 
patients/experimental animals with autoimmune dis-
eases [11], chronic viral infection [12], and cancer [13].
Alternative splicing is known to occur in up to 90% of 
genes with multiple exons [14]. Factors that influence 
alternative splicing (acidosis, hypoxia) [15–17] are also 
prominent in critical illness. The role of alternative splic-
ing and sPD-1 has not been characterized in acute condi-
tions like ARDS. Here we reveal an association between 
sPD-1 and ARDS across two species (human and mouse) 
and propose a novel mechanism for sPD-1.
Methods
Collection of human samples
Samples were obtained from patients in trauma and 
surgical intensive care units undergoing routine analy-
sis of their blood or a bronchial alveolar lavage (BAL) 
for suspected pneumonia. Patients were diagnosed with 
ARDS based on the definition provided by Bernard and 
colleagues [18] and consistent with current criteria [1]. 
Controls for the serum analysis came from ventilated, 
critically ill patients who did not have ARDS. Controls 
for BAL samples were obtained from outpatients under-
going an elective bronchoscopy. The BAL samples were 
always the first washing with saline (typically discarded). 
BAL fluid was centrifuged and the supernatant was taken 
to ensure no cells were in the samples. The Institutional 
Review Board of Rhode Island Hospital approved this 
study and waived documentation of consent (protocol 
number 211087).
Induction of indirect ARDS in mice
C57BL/6 male mice (The Jackson Laboratory, Bar Harbor, 
ME) between 10 and 12  weeks were used. Experiments 
were done according to guidelines from the National 
Institutes of Health (Bethesda, MD) and were approved 
by the Rhode Island Hospital animal use committee 
(number 0050-08). Isoflurane was used for anesthe-
sia and euthanasia was done by CO2 overdose followed 
by cardiac puncture. ARDS was induced in the mice by 
hemorrhage (non-lethal shock) followed by cecal ligation 
and puncture (CLP) [9, 19–22]. The control group was 
sham hemorrhage followed by sham CLP (Sham–Sham). 
The same aged and gender mice were used in all experi-
ments, including those utilizing ex vivo splenocytes.
Measurement of PD‑1 and sPD‑1
Blood from mice and humans was centrifuged at 
10,000×g at 4°C for 10  min, the serum layer was iso-
lated, and red blood cells were lysed with 1  mL double 
distilled water with 0.037  g EDTA (Invitrogen, Carls-
bad, CA), 8.26 g NH4Cl (Sigma, St. Louis, MO), and 1 g 
KHCO3 (Sigma, St. Louis, MO). Using the BD FACSAr-
ray, human lymphocytes were phenotyped for expression 
of PD-1 with PE labeled anti-PD-1 (Ms IgG1, Biolegend) 
and APC anti-CD3 (UCHT1, Beckman Coulter). In mice, 
PE labeled anti-PD-1 (J43, eBioscience) and APC labeled 
anti-CD3 (145-2C11, eBioscience) were used.
sPD-1 levels were assessed by ELISA. Microtiter plates 
were coated overnight with the 200  μL of sample (BAL 
fluid or serum) or a serial dilution of concentrations 
of the PD-1 Fc Chimera (R&D Systems) to serve as the 
controls. Wells were blocked and washed per standard 
ELISA protocol (R&D Systems). Anti-PD-1 antibody 
(NB110-86970, Novus Biologicals) was used for detection 
and after incubation for 2  h, anti-rabbit IgG HRP (GE 
Health Care Systems) was added, incubated for 1 h and 
plates were washed. TMB substrate solution was then 
added and incubated in the dark for 5 min. A stop solu-
tion (2 NH2SO4) was added and the optical density was 
determined at 450 nm in a microplate reader.
In order to ensure that the detected sPD-1 was the 
result of alternative splicing and not the detection of the 
membrane bound form in apoptotic bodies, the RNA 
expression was assessed. The RNA was isolated from cell 
pellets from the peripheral blood of humans in the inten-
sive care unit with and without ARDS. The RNA was iso-
lated as previously described [23]. Full length (fl) PD-1 
represents PD-1 on the cell surface while PD-1ex3 corre-
lates to sPD-1. GAPDH was used as a house-keeping gene 
and results are displayed as fold expression relative to it.
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The following primers were used for flPD-1, 
5′-TCAGGGTGACAGAGAGAAG-3′ and 5′-GACACC 
AACCACCAGGGTTT-3′; GAPDH, 5′-GTGAAGGTCG 
GAGTCAACG-3′ and 5′-TGAGGTCAATGAAGGGG 
TC-3′; PD-1ex3, 5′-AGGGTGACAGGGACAATAGG-3′ 
and 5′-CCATAGTCCACAGAGAACAC-3′.
Ex vivo experiments
Mice either underwent no surgical intervention (naïve), 
hemorrhage and CLP as above (ARDS), or underwent 
sham hemorrhage and sham CLP (control). Mice were 
male and between 10 and 12 weeks of age. Spleens from 
mice were harvested after the mice were euthanized. The 
spleens were crushed between two slides to liberate the 
cells into 10  mL sterile PBS. Red blood cells were lysed 
with sodium chloride. The solution was centrifuged down 
and cells were counted. Splenocytes were cultured with 
DMEM (Invitrogen) with 10% fetal calf serum (Atlantic 
Biologicals) and 0.1% gentamycin (Sigma).
BAL fluid from mice with ARDS (see above) was then 
added to the cultured splenocytes. In order to decipher 
the impact of sPD-1 in the BAL fluid, 5 μg of anti-PD-1 
antibody (NB110-86970, Novus Biologicals) per 50  ug 
of target protein was added and incubated overnight at 
4 °C. 200 μL of Protein A/G (Santa Cruz was added and 
incubated for 2 h at 4 °C. The fluid was then centrifuged 
at 12,000 rpm for 15 min and the supernatant collected. 
Naïve splenocytes from five different mice were cul-
tured with 50 μL of BAL fluid from mice with ARDS per 
100,000 cells in each of the above three groups.
Differing levels of a recombinant PD-1 Fc Chimera 
(R&D Systems) or IgG (R&D Systems) control was then 
used as an additive to the culture of splenocytes (as 
above) from mice with ARDS compared to mice who 
underwent sham hemorrhage and sham CLP as previ-
ously described [12, 13].
All cells were cultured for 72 h. At that point, prolifera-
tion was assessed using the CyQuant assay (Invitrogen). 
Supernatants were collected and analyzed for the pro-
duction of IL-6, IL-10, MCP-1, IFN-γ, TNF-α, and IL-12 
using the commercially available BD Cytometric Bead 
Array mouse inflammation kit (BD Biosciences, Franklin 
Lakes, NJ). In order to assess if apoptosis and subsequent 
apoptotic bodies were influencing the results of the above 
experiments, splenocytes were cultured with 0, 1000 and 
10,000 pg/mL of the fusion protein for 3 days and apop-
tosis was assessed using flow cytometry assessment of 
Annexin V (PE labeled).
Data was analyzed using SigmaPlot 10.0 (Systat Soft-
ware, San Jose, CA). Paired t tests or rank sum analysis 
were done when two groups are compared. Multiple 
groups were compared by one-way or two-way ANOVA 
with Student-Newman-Keuls correction. Graphs are dis-
played as mean or median with error bars representing 
the standard deviation. Alpha was set to 0.05.
Results
PD‑1 and sPD‑1 expression in ARDS
The expression of PD-1 on lymphocytes was compared 
in critically ill patients with ARDS (n = 21) to other ICU 
patients without ARDS (n = 9). The groups had similar 
gender distribution (38% female vs. 55%, p = 0.443) and 
APACHE II scores (22.0 vs. 19.6, p = 0.331). PaO2:FiO2 
ratio was significantly decreased in patients with ARDS 
(207.9 vs. 446.0, p < 0.001). The levels of PD-1 expression 
on CD3+ T-cells were significantly increased in patients 
with ARDS (Fig.  1c). Similar results were seen in the 
expression of PD-1 on CD3+ T-cells in mice with ARDS 
[19] compared to controls (Fig.  1d). In addition, blood 
samples from patients with ARDS had increased expres-
sion of full length PD-1 compared to ICU patients with-
out ARDS (Fig. 1e).
The systemic levels of sPD-1 were measured in ARDS 
patients and were compared to controls. The patients 
with ARDS (n = 10) had similar APACHE II scores (21.8 
vs. 21.1 p  =  0.778), age (61.5 vs. 59.8, p  =  0.835) and 
gender distribution (50% female vs. 50%, p = 0.655) but 
significantly different PaO2:FiO2 ratio (209.3 vs. 446.2 
p  <  0.001) when compared to ICU patients without 
ARDS (n = 10) (please see Table 1). The level of sPD-1 in 
the serum was significantly higher in patients with ARDS 
(11,429.3  pg/mL vs. 8061.4, p  =  0.036) (Fig.  2a). This 
data was supported by peripheral blood leukocyte gene 
expression results showing that in ARDS patients there 
was increased expression of PD-1∆Ex3 (mRNA for sPD-
1) compared to controls (Fig. 2e). In mice, a similar rise in 
the serum levels of sPD-1 was seen in those animals with 
ARDS (9396.1 vs. 3464.5 pg/mL, p = 0.001, Fig. 2b).
BAL fluid showed the levels of sPD-1 to be significantly 
higher in patients with ARDS (6311.1 vs. 90.7  pg/mL, 
p =  0.002; n =  13) when compared to controls (n =  5) 
(Fig. 2c). Age (58 vs. 62.2, p = 0.678) and gender distri-
bution (53.8% female vs. 46.2% female, p =  0.596) were 
not different between patients with ARDS and controls 
(please see Table  1). Again, a similar result was seen as 
the sPD-1 levels in the BAL fluid from mice with ARDS 
(2891.7  pg/mL) were higher compared to control mice 
(1385.9 pg/mL, p = 0.012, Fig. 2d).
F curves were plotted and sPD-1 levels in murine 
blood (AUC  =  1 (1–1), p  =  0.006), murine BAL fluid 
(AUC  =  0.905 (0.717–1.093), p  =  0.015), and human 
BAL (AUC = 1 (1–1), p = 0.001) fluid predicted ARDS. 
sPD-1 levels in human serum came close to diagnostic 
significance (AUC 0.745 (0.526–0.964), p = 0.06).
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Potential mechanism of sPD‑1’s action
To assess the biological role of sPD-1 in ARDS, BAL 
fluid from mice with ARDS was cultured with spleno-
cytes from naïve mice. When cells were cultured with 
BAL fluid from mice with ARDS, a small increase in pro-
liferation was seen compared to the BAL fluid lacking 
sPD-1 (p = 0.032, Fig. 3a). Alternatively, when basal lev-
els of cytokine production were measured between these 
three groups, no IL-10, IL-12, IFN- γ, or MCP-1 was 
detected, but cells cultured with the ARDS mouse BAL 
fluid had significantly less TNF-α production (2.7  pg/
mL) compared to cells cultured with ARDS mouse BAL 
fluid in which the sPD-1 precipitated out (52.38 pg/mL, 
p  =  0.002, Fig.  3b). Cells cultured with ARDS mouse 
BAL fluid had similar IL-6 levels when compared to cells 
exposed to ARDS mouse BAL where sPD-1 was removed 
(46.74 vs. 54.46, p = 0.234, Fig. 3c).
Splenocytes harvested from mice with/without ARDS 
may respond differently when cultured with varying 
levels of recombinant human sPD-1 we used a two-way 
analysis of variance to test the proliferative capacity of 
splenocytes from mice with and without ARDS when cul-
tured with varying levels of recombinant sPD-1 (Fig. 3a). 
Cells from mice with ARDS showed a similar degree of 
proliferation to cells taken from mice that underwent 
sham procedures (F (1, 24) =  0.753, p =  0.394). Differ-
ences in the amount of sPD-1 the cells were cultured 
with resulted in significantly different proliferation (F 
(5, 24) = 6.32, p < 0.001). The interaction of the type of 
cell (cells from mice with ARDS or control mice) and 
the amount of sPD-1 cultured with the cells was not 
significant (F (5, 24) =  0.306, p =  0.904). When assess-
ing the extent of proliferation in the presence of varying 
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Fig. 1 PD‑1 Expression on CD3+ T‑cells in the blood of humans and mice with ARDS. a Representative data showing staining and gating of human 
sample without ARDS. b Representative data showing staining and gating of human sample with ARDS. c Percent of CD3+ T‑cells in the blood 
of humans expressing PD‑1 in patients with ARDS (n = 21) compared to those without ARDS (n = 9). Analysis done by t test, *p = 0.014 when 
compared to patients without ARDS. d Percent of CD3+ T‑cells in the blood expressing PD‑1 in mice with ARDS (n = 4) compared to those without 
ARDS (n = 4). Analysis done by t test, *p = 0.05 when compared to patients without ARDS. e flPD‑1 expression in folds compared to GAPDH expres‑
sion in patients with and without ARDS. Analysis done by rank sum test. *p = 0.004 when compared to patients without ARDS












































































































































Fig. 2 Levels of soluble PD‑1 in the serum and bronchial alveolar lavage fluid of humans and mice with and without ARDS measured by ELISA. a 
sPD‑1 levels in human serum in patients with ARDS (n = 10) compared to those without ARDS (n = 10). Analysis done by t test, *p = 0.036 when 
compared to patients without ARDS. b sPD‑1 levels in mouse serum in mice with ARDS (n = 5) compared to those without ARDS (n = 6). Analysis 
done by t test, *p = 0.001 when compared to mice without ARDS. c sPD‑1 levels in human bronchial alveolar lavage fluid in patients with ARDS 
(n = 13) compared to those without ARDS (n = 5). Analysis done by t test, *p = 0.002 when compared to patients without ARDS. d sPD‑1 levels in 
mouse bronchial alveolar lavage fluid in mice with ARDS (n = 6) compared to those without ARDS (n = 7). Analysis done by t test, *p = 0.012 when 
compared to mice without ARDS. e PD‑1ex3 expression in folds compared to GAPDH expression in patients with and without ARDS. Analysis done 
by rank sum test. *p = 0.002 when compared to patients without ARDS
Table 1 Demographic and clinical data of human samples
Demographics of patients whose serum sPD‑1 was assessed
ARDS (n = 10) No ARDS (n = 10) p value
Age 62 60 0.835
Female 50% 50% 0.655
APACHE II 22 21 0.778
PaPO2:FiO2 209 357 <0.001
sPD‑1 level 11,429 pg/mL 8061 pg/mL 0.036
Demographics of patients whose BAL fluid sPD‑1 was assessed
ARDS (n = 13) No ARDS (n = 5) p value
Age 58 62 0.678
Female 58% 62% 0.596
sPD‑1 level 6311 pg/mL 90.7 pg/mL 0.002
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significantly more (p < 0.05) proliferation compared to 0 
and 1000,000 pg/mL of sPD-1 (Fig. 3a).
Culturing cells from ARDS mice with/without vary-
ing concentrations of recombinant sPD-1 led to differ-
ences in cytokine release when compared to cells derived 
from sham animals cultured with similar concentra-
tion of sPD-1. To ensure apoptotic bodies did not influ-
ence the findings of these ex vivo experiments, Annexin 
V expression was similar on cells cultured with 0, 1000 
and 10,000 pg/mL of the fusion protein (0.5, 0.6, 0.7%, p 
0.33). Similar apoptosis was not due to lack of prolifera-
tion (6.1 × 104, 6.6 × 104, 6.7 × 104, p = 0.87). In cells 
from mice with ARDS, while a modest rise in the pro-
duction of TNF-α could be seen in the cells treated with 
sPD-1, this increase was not statistically significant. Fur-
ther the presence of increasing concentrations of sPD-1 
did not alter ARDS mouse splenocyte TNF-α release 
(p = 0.701, Fig. 4b). Alternatively, TNF-α production by 
cells from Sham-control mice when cultured at 1000 pg/
mL of sPD-1 rose significantly when compared to either 
the 0 pg sPD-1 treated cells or cells derived ARDS mice 
also treated with 1000  pg/mL (p =  0.033, Fig.  4b). This 
rise was, however, transient in nature for as recombinant 
sPD-1 levels were increased the production of TNF-α 
was markedly suppressed. With regards to IL-10, IFN-γ 
and IL-6 we saw essentially the same affect of sPD-1 
treatment on the production of these mediators by 
















































Fig. 3 Outcomes of cells cultured with BAL fluid from mice with ARDS. a Proliferation of splenocytes from naïve mice cultured with BAL fluid from 
mice with ARDS (BAL, n = 5, experiments in triplicate) compared to cells cultured with BAL fluid where the sPD‑1 was precipitated out (Anti‑sPD‑1, 
n = 5, experiments in triplicate) Analysis done by t test, *p = 0.032 when compared to cells cultured with BAL fluid where sPD‑1 was precipitated 
out. b TNF‑α levels of splenocytes from naïve mice cultured with BAL fluid from mice with ARDS (BAL, n = 5) compared to cells cultured with BAL 
fluid where the sPD‑1 was precipitated out (Anti‑sPD‑1, n = 5) Analysis done by t test, *p = 0.002 when compared to cells cultured with BAL fluid 
from mice with ARDS. c IL‑6 levels of splenocytes from naïve mice cultured with BAL fluid from mice with ARDS (BAL, n = 5) compared to cells 
cultured with BAL fluid where the sPD‑1 was precipitated out (Anti‑sPD‑1, n = 5)
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Discussion
Previous research on PD-1 has focused on chronic 
inflammatory conditions. Here we have examined the 
expression of PD-1 using ARDS as a model disease for 
an acute response. In humans and mice with ARDS, 
the circulating T-cells exhibit increased levels of PD-1 
and its gene expression (Fig.  1). Previous research has 
shown that in mice with ARDS there is increased expres-
sion of PD-1 not only on T-cells but also on neutrophils 
and dendritic cells in the lung [9]. As such, the relative 
decrease in number of CD-3 lymphocytes in ARDS is 
not as concerning since there is a global increase (across 
many cell lines) in PD-1 expression in mice and humans 
with ARDS.
The role of sPD-1 has not been consistent among dis-
eases associated with elevated PD-1. Increases in sPD-1 
were not seen in some diseases [24] but elevations were 
present in arthritis [23] and aplastic anemia [11]. Simi-
lar concomitant elevations of sPD-1 are seen in mice and 
humans with ARDS (Fig.  2a–d). The findings of a dis-
tinct protein and not just detection of membrane bound 
PD-1 in apoptotic bodies were further supported by the 
increased RNA expression of PD-1∆Ex3 (the alternative 
splice variant of PD-1 gene) in ARDS patients (Fig. 2e).
Experiments were done to assess the impact of sPD-1 
on the immune system. In splenocytes from mice with-
out ARDS there was reduced expression of TNF-α when 
exposed to BAL fluid with sPD-1 as compared to BAL 



































































0           1,000          2,500          5,000          10,000
Splenocytes from mice without ARDS
Splenocytes from mice with ARDS
b c
ed
0           1,000       2,500       5,000     10,000    1,000,000
a
*† *† *† *†
0           1,000          2,500          5,000          10,000 0           1,000          2,500          5,000          10,000












Fig. 4 Outcome of cells cultured with varying levels of sPD‑1 a Proliferation of splenocytes from mice with ARDS (n = 4, experiments in triplicate) 
compared to mice without ARDS (n = 4, experiments in triplicate). Analysis done by two‑way ANOVA with Student‑Newman‑Keuls method used 
for multiple comparisons. *p < 0.05 when that amount is compared to 0 ng/mL regardless of whether the cells came from a mouse with ARDS. 
†p < 0.05 when that amount is compared to 1000 ng/mL regardless of whether the cells came from a mouse with ARDS. b TNF‑α levels from sple‑
nocytes of mice with ARDS (n = 4) compared to mice without ARDS (n = 4) #p < 0.05 when cells from mice with ARDS are compared to cells from 
sham mice at that level of sPD‑1 ‡p < 0.05 when comparing cells from sham mice to a sPD‑1 level of 1 ng/mL c IL‑6 levels from splenocytes from 
mice with ARDS (n = 4) compared to mice without ARDS (n = 4) ‡p < 0.05 when comparing cells from sham mice to a sPD‑1 level of 1 ng/mL d 
IFN‑γ levels from splenocytes from mice with ARDS (n = 4) compared to mice without ARDS (n = 4) #p < 0.05 when cells from mice with ARDS are 
compared to cells from sham mice at that level of sPD‑1 ‡p < 0.05 when comparing cells from sham mice to a sPD‑1 level of 1 ng/mL e IL‑10 levels 
from splenocytes from mice with ARDS (n = 4) compared to mice without ARDS (n = 4) #p < 0.05 when cells from mice with ARDS are compared to 
cells from sham mice at that level of sPD‑1 ‡p < 0.05 when comparing cells from sham mice to a sPD‑1 level of 1 ng/mL
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fluid where sPD-1 been absorbed out (Fig.  3b). This 
speaks to the notion that the PD-1 system alters cytokine 
release/production, particularly TNF-α [25].
In ex vivo experiments, splenocytes derived from mice 
with ARDS or controls were used to further identify the 
role of sPD-1. PD-1 signaling has a greater influence on 
the production of cytokines than the regulation of pro-
liferation [25]. We noted a transient increase, at 1  ng/
mL sPD-1 treatment, in cytokine (Fig.  4b–e) release by 
cells derived from non-ARDS mice over the 0 ng sPD-1 
treated group, no such change was seen in cells from 
ARDS mice vs. 0  ng sPD-1 group (Fig.  4b–e). This sug-
gests splenocytes in ARDS may be an “exhausted cell” 
phenotype that has been reported in chronic viral infec-
tion [26]. Along these lines it’s worth noting that while 
increasing the concentration of sPD-1 (2.5–10  ng/mL 
sPD-1) in culture ablated the rise in cytokine release 
detected in 1  ng/mL sPD-1 treatment group, no effects 
were evident in cells derived from ARDS mice. (Fig.  4b–
e). Interestingly, “exhaustion” could also pertain to IFN-γ 
as cells from mice with ARDS were not stimulated to 
produce this cytokine with the addition sPD-1. sPD-1 has 
been suggested as a treatment for “exhaustion” in chronic 
viral conditions, but recent work suggests stimulation of 
IFN-γ with sPD-1 may require the addition of another 
adjuvant molecule [27].
Animal models of ARDS are associated with increased 
levels of IL-6, MCP-1, and TNF-α [9, 19]. TNF-α is 
elevated and thought to be responsible for the patho-
logic changes that occur in ARDS [28–30]. BAL fluid 
from mice with ARDS reduces TNF-α production when 
sPD-1 is present. TNF-α is known to be directly influ-
enced by PD-1 ligation [25]. In PD-1 deficient animal’s 
survival after ALI is improved and TNF-α production 
is drastically reduced in their lungs [9]. Here we suggest 
that sPD-1 ligation with PD-1 leads to a reduction in the 
TNF-α production, akin to the lack of TNF-α production 
seen in PD-1 deficient mice with ARDS. The capacity 
of sPD-1 in ARDS mouse BAL to decrease TNF-α level 
that we have shown here may in fact represent aspects of 
an endogenous mechanism directed at suppressing the 
inflammatory response associated ARDS in an attempt to 
dampen the immune system and improve outcomes.
T-cells from patients with aplastic anemia [11] and 
arthritis [23] that were cultured with recombinant sPD-1 
lead to increased proliferation of the T-cells due to sPD-1 
blocking PD-L1 [31]. In our experiment, culturing sple-
nocytes with sPD-1 did result in increased proliferation, 
but this effect was comparable irrespective of whether 
or not the cells had been derived from animals with or 
without ARDS (Fig.  4a). When levels of protein were 
increased to 1000 ng/mL there was a decrease in prolif-
eration compared to physiological levels (1–10  ng/mL, 
Fig.  2). These findings are consistent with data suggest-
ing T cells and dendritic cells should be co-cultured [32] 
rather than purified T cells, as done in aplastic anemia 
and arthritis studies [11, 23, 31].
The resultant decline in proliferation seen at high con-
centrations of sPD-1 may be due to stimulation of PD-1 
with sPD-1. PD-1 ligation is associated with decreased 
Bcl-xL [33] and its possible ligation of PD-1 by sPD-1 
causes Bcl-xL levels to drop to where apoptosis predomi-
nates. Previous studies culturing T cells and dendritic 
cells with sPD-1 have suggested a similar explanation 
[32].
In mice and humans with ARDS sPD-1 is increased in 
both the serum and the BAL fluid; suggesting its value 
as a possible biomarker. In addition ROC curves pre-
dicted ARDS when looking at human and mouse BAL 
and mouse serum. In this study, we did not have matched 
pairs of blood and BAL samples to assess the impact of 
the combined levels in predicting ARDS. This potential 
use of sPD-1 as a biomarker must be studied further and 
include other clinical scores and biomarkers.
Conclusion
We propose the release sPD-1 may attempt to dampen 
the immune response, as demonstrated by reduced cell 
proliferation and decreased cytokine production at phys-
iological levels of sPD-1 and its presence could act as a 
potential biomarker in ARDS.
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